Steris PLC (STE), the multinational medical equipment company, reportedly posted healthy Q4 2025 earnings, achieving strong revenue growth and broadening profit margins, beating estimates and resulting in a rising stock price. The firm has adjusted its fiscal 2026 outlook, aiming for 6-7% revenue growth and EPS of $9.90-$10.15 despite tariff-related obstacles. Financial analysts have responded favorably, with price target upgrades from both Citizens JMP and JMP Securities.
Steris's robust financial records for fiscal 2025 and forecasts of continued growth have gained market attention. However, despite the positive fiscal Q4 figures, a cautious sentiment towards the health care industry has influenced the company's stock price. Morgan Stanley has increased the company's price target to $260 from $240, reflecting the optimistic outlook for Steris.
The firm has been focusing on strategic acquisitions to bolster its position amidst macroeconomic challenges, which has been positively received by the market. Steris has made progress in its AST Recovery, resulting in an upgrade to 'Strong Buy'. With a dividend of $0.57 per share declared, Steris continues to be an attractive option for investors.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 17 May 2025 06:08:53 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -2
